183
Views
27
CrossRef citations to date
0
Altmetric
Original Research

Prediction models for exacerbations in different COPD patient populations: comparing results of five large data sources

, , , , , , , & show all
Pages 3183-3194 | Published online: 01 Nov 2017

References

  • DonaldsonGCSeemungalTABhowmikAWedzichaJARelationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary diseaseThorax2002571084785212324669
  • CelliBRThomasNEAndersonJAEffect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH studyAm J Respir Crit Care Med2008178433233818511702
  • Soler-CatalunaJJMartinez-GarciaMARoman SanchezPSalcedoENavarroMOchandoRSevere acute exacerbations and mortality in patients with chronic obstructive pulmonary diseaseThorax2005601192593116055622
  • HoogendoornMHoogenveenRTRutten-van MolkenMPVestboJFeenstraTLCase-fatality of COPD exacerbations: a meta-analysis and statistical modeling approachEur Respir J201137350851520595157
  • MiravitllesMFerrerMPontAZalacainREffect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up studyThorax200459538739515115864
  • SeemungalTADonaldsonGCPaulEABestallJCJeffriesDJWedzichaJAEffect of exacerbation on quality of life in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med19981575141814229603117
  • SpencerSCalverleyPMBurgePSJonesPWImpact of preventing exacerbations on deterioration of health status in COPDEur Respir J200423569870215176682
  • AnderssonFBorgSJanssonSAThe costs of exacerbations in chronic obstructive pulmonary disease (COPD)Respir Med200296970070812243316
  • OostenbrinkJBRutten-van MolkenMPResource use and risk factors in high-cost exacerbations of COPDRespir Med200498988389115338802
  • O’ReillyJFWilliamsAERiceLHealth status impairment and costs associated with COPD exacerbation managed in hospitalInt J Clin Pract20076171112112017577296
  • Global Initiative for chronic Obstructive Lung Disease (GOLD)Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease2013
  • CrinerGJBourbeauJDiekemperRLPrevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society GuidelineChest2015147489494225321320
  • HoogendoornMFeenstraTLAsukaiYPatient heterogeneity in health economic decision models for chronic obstructive pulmonary disease: are current models suitable to evaluate personalized medicine?Value Health201619680081027712708
  • HurstJRVestboJAnzuetoAEvaluation of COPD longitudinally to identify predictive surrogate endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary diseaseN Engl J Med2010363121128113820843247
  • BeehKMGlaabTStowasserSCharacterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trialRespir Res201314111624168767
  • BriggsASpencerMWangHManninoDSinDDDevelopment and validation of a prognostic index for health outcomes in chronic obstructive pulmonary diseaseArch Intern Med20081681717918195198
  • MakeBJErikssonGCalverleyPMA score to predict short-term risk of COPD exacerbations (SCOPEX)Int J Chron Obstruct Pulmon Dis20151020120925670896
  • NiewoehnerDELokhnyginaYRiceKRisk indexes for exacerbations and hospitalizations due to COPDChest20071311202817218552
  • JenkinsCRCelliBAndersonJASeasonality and determinants of moderate and severe COPD exacerbations in the TORCH studyEur Respir J2012391384521737561
  • BertensLCReitsmaJBMoonsKGDevelopment and validation of a model to predict the risk of exacerbations in chronic obstructive pulmonary diseaseInt J Chron Obstruct Pulmon Dis2013849349924143086
  • MullerovaHShuklaAHawkinsAQuintJRisk factors for acute exacerbations of COPD in a primary care population: a retrospective observational cohort studyBMJ Open2014412e006171
  • McGarveyLLeeAJRobertsJGruffydd-JonesKMcKnightEHaughneyJCharacterisation of the frequent exacerbator phenotype in COPD patients in a large UK primary care populationRespir Med2015109222823725613107
  • HoogendoornMFeenstraTLAsukaiYCost-effectiveness models for chronic obstructive pulmonary disease: cross-model comparison of hypothetical treatment scenariosValue Health201417552553625128045
  • ReganEAHokansonJEMurphyJRGenetic epidemiology of COPD (COPDGene) study designCOPD201071324320214461
  • MontnemeryPAdelrothEHeumanKPrevalence of obstructive lung diseases and respiratory symptoms in southern SwedenRespir Med199892121337134510197227
  • KruisALBolandMRSchoonveldeCHRECODE: design and baseline results of a cluster randomized trial on cost-effectiveness of integrated COPD management in primary careBMC Pulm Med20131311723522095
  • VestboJAndersonWCoxsonHOECLIPSE investigatorsEvaluation of COPD longitudinally to identify predictive surrogate end-points (ECLIPSE)Eur Respir J200831486987318216052
  • DecramerMCelliBTashkinDPClinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT trialCOPD20041230331217136995
  • KeeneONCalverleyPMJonesPWVestboJAndersonJAStatistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisitedEur Respir J2008321172418591336
  • Al-aniSSpigtMHofsetPMelbyeHPredictors of exacerbations of asthma and COPD during one year in primary careFam Pract201330662162824115012
  • HuseboGRBakkePSAanerudMPredictors of exacerbations in chronic obstructive pulmonary disease: results from the Bergen COPD cohort studyPLoS One2014910e10972125279458
  • KilicHKokturkNSariGCakirMDo females behave differently in COPD exacerbation?Int J Chron Obstruct Pulmon Dis20151082383025977604
  • OwensGMGender differences in health care expenditures, resource utilization, and quality of careJ Manag Care Pharm20081432618439060
  • KerkhofMFreemanDJonesRChisholmAPriceDBEffectiveness GroupPredicting frequent COPD exacerbations using primary care dataInt J Chron Obstruct Pulmon Dis2015102439245026609229